Cite

HARVARD Citation

    Chenard-Poirier, M. et al. (n.d.). 1184PA phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. Annals of oncology. p. . [Online]. 
  
Back to record